Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating two different pacing methods for patients with slow heart rates, called bradycardia. This study compares the common right ventricular pacing approach with a newer physiological pacing method that includes His bundle and left bundle area pacing. The trial aims to better understand how these pacing techniques affect patient outcomes, including mortality and heart failure morbidity, in a large group of 2600 patients. Participants will receive a pacemaker implant and be randomly assigned to either right ventricular pacing or physiological pacing. The physiological pacing may involve His bundle pacing or left bundle pacing, but if these are not successful, biventricular pacing will be used. A subgroup of 500 participants will take part in an optional echocardiographic sub-study to assess heart function changes over a 24-month period. Throughout the study, patients will be assessed at baseline and every six months after randomization, with follow-up lasting up to 78 months. Researchers will monitor outcomes such as mortality, heart failure events, device-related safety issues, patient quality of life, symptoms, and pacemaker-derived data like arrhythmias and activity levels. The echocardiographic sub-study will measure specific heart function changes to understand pacing-induced cardiomyopathy. Participants involvement includes implantation, regular follow-up visits, questionnaires, and optional imaging assessments.
Actively Recruiting
Researchers are evaluating whether less frequent dosing of pembrolizumab after six months of standard treatment is safe and effective for patients with advanced non-small cell lung cancer NSCLC. Pembrolizumab, an immunotherapy targeting the PD-1 receptor, has improved outcomes in NSCLC, but current dosing every six weeks for up to two years may result in overtreatment. This UK phase III trial aims to find if reducing dose frequency can maintain effectiveness while improving quality of life and lowering costs. Participants who have received six months of pembrolizumab, with or without chemotherapy, and plan to continue treatment will be randomized to receive pembrolizumab intravenously every six weeks control or every twelve weeks initially. If the 12-week dosing is found to be not less effective, additional groups receiving doses every nine, fifteen, and eighteen weeks will be included. Patients who experience disease progression while on reduced frequency dosing can return to the standard six-week schedule. Throughout the study, participants will be monitored for overall survival at 18 months from randomization, along with other outcomes such as progression-free survival, response rate, duration of response, and adverse events over two years. The study involves regular hospital visits for treatment and assessments, and the results may lead to safer, more convenient treatment options for NSCLC patients. The total participation time varies depending on individual treatment and follow-up schedules.
Actively Recruiting
Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.
Actively Recruiting
Researchers are evaluating the combination of bleximenib with venetoclax VEN and azacitidine AZA compared to placebo with VEN and AZA alone for treating adults newly diagnosed with Acute Myeloid Leukemia AML who have specific gene mutations in NPM1 or KMT2A. This phase 3 randomized, double-blind study is designed for participants ineligible for intensive chemotherapy, aiming to understand how these treatments work in this population. Participants will receive treatment in 28-day cycles until disease progression or unacceptable side effects occur. One group will take oral bleximenib alongside oral venetoclax and intravenous or subcutaneous azacitidine, while the other group receives a placebo plus venetoclax and azacitidine. Treatment continues with regular cycles, and the study monitors effects over time. Throughout the study, participants will be assessed for response, including complete remission rates and overall survival, for up to more than four years. Researchers will also track event-free survival, duration and timing of remission, transfusion independence, adverse events, and blood levels of bleximenib. Safety and laboratory tests will be conducted regularly to monitor participant health and treatment effects.
Actively Recruiting
Researchers are evaluating the long-term outcomes of the ACE Acetabular Cup System, a device used in total hip replacement surgery. This procedure replaces both the hip ball and socket to relieve pain and help patients return to normal activities. The study aims to monitor the safety and performance of this CE-marked device over 10 years by assessing clinical, functional, and radiological results in patients with hip disease. The ACE Acetabular Cup System offers three options for socket liners ceramic, polymer, or dual mobility, allowing surgeons to choose the best fit for each patient. Participants in the study have received a primary elective total hip replacement using this system combined with a JRI femoral stem and head. The study is observational and follows patients over a decade to gather data on device function and patient health. Participants will be followed through questionnaires, reviews of X-rays, and monitoring of any complications. Key measurements include the Oxford Hip Score at 3 years post-operation, along with implant survivorship and other hip function assessments at multiple time points up to 10 years. Radiological assessments will also be conducted at 1, 5, and 10 years. This comprehensive follow-up helps researchers understand how well the device performs long-term and supports patient safety.
Actively Recruiting
This research aims to assess the effectiveness and safety of adding oral anticoagulation OAC to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation POAF after isolated coronary artery bypass graft CABG surgery. The study is a prospective, multicenter, open-label, randomized trial comparing OAC with no OAC to evaluate the prevention of thromboembolic events and the risk of major bleeding. Participants are randomly assigned to either an OAC-based strategy using vitamin K antagonists or approved direct oral anticoagulants alongside antiplatelet therapy, or to an antiplatelet-only strategy. The anticoagulation treatment lasts for 90 days, with option for crossover to OAC if recurrent atrial fibrillation occurs after 30 days in the control group. Up to 500 patients may also participate in a digital health substudy using a wearable heart rhythm monitor for 30 days post-discharge. During the study, participants have follow-up visits at 30, 60, 90, and 180 days after randomization, including phone contacts and clinical assessments. Researchers will monitor outcomes such as death, stroke, transient ischemic attacks, myocardial infarction, thromboembolism, and bleeding events up to 180 days. Data from patients who decline randomization are collected in a parallel registry to compare baseline risk and treatment strategies.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of whole-body hypothermia for newborn babies with mild hypoxic ischaemic encephalopathy. This phase III randomised controlled trial aims to determine whether cooling the whole body to 33.5.5C within six hours after birth and continuing for 72 hours improves cognitive development at around two years of age compared with maintaining normal body temperature. The study also seeks to assess the economic value of cooling therapy for mild encephalopathy within the healthcare system. Babies born at or after 36 weeks with signs of birth asphyxia or acidosis will be randomly assigned to receive either whole-body hypothermia or targeted normothermia. Cooling will be applied using a servo-controlled machine in neonatal intensive care units, maintaining a rectal temperature of about 33.5C for 72 hours. The control group will have their body temperature kept at normal levels 37C for the first 80 hours, with any fever carefully treated. Babies born at non-cooling centers will be transferred to specialized units for treatment. During the study, participants will undergo brain monitoring, MRI scans before discharge, and follow-up developmental assessments at 24 months using the Bayley Scales of Infant and Toddler Development IV. Additional evaluations will include neurological exams, motor function assessments, vision and hearing tests, and parent-completed questionnaires. Researchers will collect detailed clinical data from birth through hospital stay, aiming to compare cognitive outcomes and safety measures between the two groups over the study period.
Actively Recruiting
Atrial fibrillation AF is a common heart rhythm disorder that can lead to serious complications like stroke. This trial focuses on patients with AF who have experienced an ischemic stroke despite being on anticoagulant therapy, which still leaves a risk of stroke. Researchers want to find out if adding left atrial appendage occlusion LAAO to direct oral anticoagulant DOAC treatment offers better protection against stroke compared to DOAC therapy alone. Participants will be randomly assigned to one of two groups one receiving both LAAO and DOAC therapy, and the other receiving only DOAC therapy. The choice of DOAC is made by the treating doctor. The study uses a PROBE design with blinded outcome assessment and plans to enroll about 482 patients. The minimum follow-up period is 6 months, with visits every 6 months up to a maximum of 48 months. During the study, participants will undergo assessments to monitor for recurrent stroke, systemic embolism, cardiovascular death, bleeding events, device or procedure complications, and overall health and function. Follow-up visits will continue every 6 months until the study ends or the maximum follow-up duration is reached. Researchers will measure outcomes like stroke recurrence, safety, functional neurological status, and hospitalizations to evaluate the benefits and risks of the treatments.
Actively Recruiting
Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.
Actively Recruiting
Researchers are studying a medicine called elranatamab to treat multiple myeloma MM, a type of cancer. This study compares elranatamab with other common combination therapies for people with MM that has returned or not responded to previous treatments, including anti-CD38 antibody and lenalidomide. The study is sponsored by Pfizer and is a phase 3, open-label trial evaluating treatment options for adults with relapsed or refractory MM. Participants will be randomly assigned to receive either elranatamab alone or one of several combination therapies chosen by the study doctor. Elranatamab is given as a shot under the skin at the clinic about once a week, which may reduce in frequency later. Combination therapies include two to three different medicines taken orally or by injection at the clinic, with dosing schedules depending on the selected regimen. Treatment continues until the disease no longer responds. During the study, participants will have regular clinic visits to monitor their response and safety while receiving treatment. After treatment ends, follow-up will be done by phone or clinic visits. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, duration of response, and quality of life over approximately five years. Safety and laboratory tests will also be monitored throughout and shortly after treatment completion.
1-10 of 15
1